Corologic

Cover Block

Open sources

Field	Detail
Name	Corologic
Tagline	AI software that restores low-frame-rate coronary angiography to reduce X-ray exposure. [corologic.io]
Headquarters	Seoul, South Korea [Seoul Economic Daily, September 2026]
Founded	2026 [Seoul Economic Daily, September 2026]
Stage	Seed [Seoul Economic Daily, September 2026]
Business model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	East Asia
Growth profile	Venture Scale
Founding team	Academic Spinout [Seoul Economic Daily, September 2026]
Funding label	Undisclosed [KORIT, September 2026]

Links

Open sources

• Website: https://www.corologic.io/

What an Investor Needs First

PUBLIC Corologic is a Seoul-based cardiovascular imaging startup building AI software that reconstructs low-frame-rate coronary angiography in real time, a timely proposition because it sits at the intersection of dose reduction, cath-lab workflow, and software-based imaging improvement rather than new imaging hardware replacement [Seoul Economic Daily, September 2026] [Asia Economy, September 2026] [corologic.io]. The company was founded in May 2026 and emerged from work tied to Seoul National University Bundang Hospital, which gives the story more clinical specificity than a typical early imaging-AI launch, even if commercial adoption is still unproven in public sources [Seoul Economic Daily, September 2026] [KORIT, September 2026].

Its lead product, Angio-FILM, is described as a software medical device for the cardiac catheterization laboratory that uses AI-based video-frame interpolation to restore intermediate frames from low-frame-rate coronary angiography, with the stated aim of lowering X-ray exposure for patients and staff while preserving usable motion detail in procedure video [Asia Economy, September 2026] [LinkedIn] [corologic.io]. That differentiation matters if it holds up clinically, because the pitch is not generic image analysis but real-time reconstruction inside an existing interventional imaging workflow, reportedly with on-prem deployment and an early Korean regulatory registration completed on August 3, 2026 according to a team member's LinkedIn profile [corologic.io] [LinkedIn].

The publicly surfaced team is relevant to the problem set: Sihyuck Kang is identified as a cardiology professor and cardiovascular intervention specialist at Seoul National University Bundang Hospital, KyungRae Hwang is reported to bring 24 years in the medical-device industry, and Youngrak Choi is described as having experience across cardiovascular angiography equipment, clinical workflow, and medical-imaging AI [KORIT, September 2026] [LinkedIn]. Corologic raised an undisclosed seed round in September 2026 from Kakao Ventures and Seoul National University Technology Holdings, and the company is categorized here as a hardware-plus-software healthtech business, though the public materials center more heavily on the software layer than on any proprietary device component [Seoul Economic Daily, September 2026] [Asia Economy, September 2026].

Over the next 12 to 18 months, the main things to watch are whether Corologic can convert technical credibility into multicenter clinical validation, secure broader regulatory progress in Korea and eventually the U.S., and show evidence of hospital adoption beyond its academic origin point [Asia Economy, September 2026] [Seoul Economic Daily, September 2026]. At this stage, investor interest rests less on disclosed traction, which is thin in public reporting, and more on whether the company can prove that lower-frame-rate acquisition plus AI reconstruction improves the dose-performance tradeoff without disrupting cath-lab practice [VentureSquare, October 2026] [corologic.io].

Partially corroborated -- Based primarily on named media coverage, company materials, and LinkedIn profiles; several product and team claims have only single-source or company-source corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Undisclosed

Inside the Company

PUBLIC Corologic presents as a very new Seoul-based cardiovascular imaging startup, with the public record still narrow enough that chronology matters more than narrative flourish. The company website positions the business around lower-dose coronary angiography restored by AI, and lists Seoul as its base, while the public summary tied to that site places founding in May 2026 and links the effort to Seoul National University Bundang Hospital [corologic.io, retrieved 2026].

The early milestone sequence is unusually compressed, at least in the sources available. Corologic states that it is building on-premise clinical imaging software for lower-dose coronary angiography through its Angio-FILM product, and a LinkedIn post cited in the source set reports that Angio-FILM completed Korean regulatory registration on August 3, 2026, roughly three months after founding [corologic.io, retrieved 2026] [LinkedIn, retrieved 2026]. That does not, on its own, establish commercial deployment, but it does suggest the company entered the market with a product and regulatory agenda already in motion [LinkedIn, retrieved 2026].

Public financing followed quickly after launch. Corologic's site and contemporaneous coverage identify the company as the developer of Angio-FILM, and Seoul Economic Daily reported in September 2026 that Corologic had raised an undisclosed seed round from Kakao Ventures [corologic.io, retrieved 2026] [Seoul Economic Daily, September 2026]. The same September coverage names Seoul National University Technology Holdings as a participating investor, which fits the academic spinout profile implied by the company's hospital origin and technical focus [Seoul Economic Daily, September 2026] [Asia Economy, September 2026].

Partially corroborated -- Founded date and headquarters rely primarily on the company website, with partial corroboration from named-publisher coverage.

Under the Hood

MIXED

What is concrete here is narrower than the company narrative, but still specific enough to describe the product wedge. Corologic says its lead product, Angio-FILM, reconstructs low-frame-rate coronary angiography video in real time, with the stated aim of reducing X-ray exposure for patients and clinical staff during cardiac catheterization procedures [corologic.io] [Asia Economy, September 2026]. Asia Economy describes the core method as AI-based video-frame interpolation that restores intermediate frames in low-frame-rate coronary angiography footage, while the company site frames the product as lower-dose coronary angiography reconstruction for on-prem clinical imaging workflows [Asia Economy, September 2026] [corologic.io].

The intended use setting also appears reasonably clear from public material. A LinkedIn profile for Jayden Won describes Angio-FILM as a software medical device for the cardiac catheterization laboratory and states that Korean regulatory registration was completed on August 3, 2026, roughly three months after the company's May 2026 founding date cited in press coverage [LinkedIn] [Seoul Economic Daily, September 2026]. That timing is notable if accurate, although the registration claim is only singly sourced in the public record reviewed here [LinkedIn].

Public reporting also sketches the next layer of technical and commercial proof points without establishing them as completed milestones. Asia Economy reported that Corologic planned multicenter clinical validation, Korean MFDS approval work, U.S. FDA 510(k) clearance, and ISO 13485 certification after its seed financing [Asia Economy, September 2026]. For now, the product case rests on a plausible and clinically legible premise, fewer acquired X-ray frames with software restoration to preserve visual continuity, but the public record does not yet show named deployment sites, published validation data, or verified performance metrics.

Partially corroborated -- Based on one independent press description of the core method, partial corroboration from the company website, and single-source support for the regulatory registration claim.

Market Research

PUBLIC

The market matters now because Corologic is trying to sell into an imaging workflow where clinical demand is established, radiation exposure is a persistent constraint, and hospitals are already accustomed to regulated device purchasing rather than discretionary software experiments [Asia Economy, September 2026] [VentureSquare, October 2026].

The public record does not provide a named third-party TAM, SAM, or SOM for Corologic specifically, so the evidence here has to stay narrower. What is established is the clinical setting: Angio-FILM is described as a software medical device for the cardiac catheterization laboratory, and its function is tied to coronary angiography rather than general-purpose radiology or broad hospital IT [LinkedIn] [Asia Economy, September 2026]. That narrows the initial market to interventional cardiology imaging workflows, with expansion depending on whether the same frame-reconstruction approach can travel into adjacent fluoroscopy-heavy procedures, a point the current sources do not confirm [corologic.io] [Seoul Economic Daily, September 2026].

Demand drivers are clearer than market size. Multiple sources describe the product around one operational claim: acquire lower-frame-rate coronary angiography footage, reconstruct intermediate frames in real time, and reduce X-ray exposure for patients and staff while preserving a clinically usable view of vessel motion and procedure flow [Asia Economy, September 2026] [VentureSquare, October 2026] [corologic.io]. If that claim holds in routine use, the budget case would likely sit at the intersection of cath lab throughput, staff safety, and image-quality preservation rather than a stand-alone AI line item, which is relevant because hospitals typically fund imaging upgrades through clinical and regulatory justification first [Seoul Economic Daily, September 2026] [EDAILY, September 2026].

The adjacent markets are easier to define than the core market's revenue pool. Corologic sits next to coronary angiography equipment, cath lab imaging software, dose-reduction tools, and broader medical-imaging AI, but the company is not presented in public sources as a full imaging-platform vendor or a capital-equipment manufacturer [KORIT, September 2026] [Asia Economy, September 2026]. That positioning matters because substitute options may include existing hardware settings, workflow changes, or vendor-supplied image-processing features, not just direct startup competition. The commercial question is whether buyers view frame reconstruction as a distinct software category or as a feature that belongs inside incumbent imaging systems, and the available reporting does not settle that [VentureSquare, October 2026] [corologic.io].

Regulation is not a side issue here, it is part of the market definition. Asia Economy reports that Corologic plans multicenter clinical validation, Korean Ministry of Food and Drug Safety approval, U.S. FDA 510(k) clearance, and ISO 13485 certification, which implies a market path shaped by evidence generation and quality-system execution as much as by product demand [Asia Economy, September 2026]. Jayden Won's LinkedIn profile also states that Angio-FILM completed Korean regulatory registration on August 3, 2026, three months after the company's founding, but that remains a single-source claim and should be treated cautiously until corroborated through a regulator or company filing [LinkedIn].

Market lens	Publicly supported claim	Source
Core use case	Coronary-angiography video reconstruction in real time	[Asia Economy, September 2026]
Initial workflow	Cardiac catheterization laboratory software medical device	[LinkedIn]
Economic driver	Potential reduction in X-ray exposure for patients and staff	[VentureSquare, October 2026] [corologic.io]
Go-to-market gate	Multicenter validation plus MFDS, FDA 510(k), and ISO 13485 path	[Asia Economy, September 2026]

The table shows a market that is legible by workflow and procurement logic, but still thin on external sizing. For now, the investable point is not category scale on paper, it is whether radiation reduction and image continuity are important enough in cath lab practice to justify a new regulated software purchase.

Partially corroborated -- Section relies on named public sources for product scope and regulatory path, but no independent third-party TAM/SAM/SOM or market-size dataset was identified.

Competition and Substitutes

MIXED Corologic is positioning itself against a mix of entrenched angiography-system vendors, imaging software specialists, and the status quo of running coronary angiography at higher frame rates rather than reconstructing missing frames in software [Asia Economy, September 2026] [corologic.io] [VentureSquare, October 2026].

The segment map is clearer than the company list. At the incumbent end, the practical alternative is the installed base of cath-lab imaging platforms sold by large medical-device companies, because those systems already control image acquisition and workflow inside coronary angiography suites, even if the reviewed sources do not name specific vendors [Asia Economy, September 2026]. At the challenger end, Corologic is trying to carve out a narrower wedge as a software medical device for cardiac catheterization labs, centered on AI-based frame interpolation rather than full hardware replacement [LinkedIn] [Asia Economy, September 2026]. The adjacent substitute is simpler and more immediate: hospitals can continue using conventional frame rates and accept the existing radiation tradeoff, which means Corologic is not only competing with companies, but with an established clinical operating habit [VentureSquare, October 2026] [corologic.io].

Its edge today appears to be domain specificity rather than scale. The public record ties the company to Seoul National University Bundang Hospital, identifies Sihyuck Kang as both a cardiology professor and co-inventor of the core technology, and describes Youngrak Choi and KyungRae Hwang as bringing imaging-product and medical-device operating experience to the founding team [Seoul Economic Daily, September 2026] [KORIT, September 2026]. That combination matters because coronary angiography is a narrow, workflow-sensitive environment, and products that claim real-time reconstruction inside the procedure room have to fit clinical practice, not just score well on a generic vision benchmark [Asia Economy, September 2026] [LinkedIn]. The same edge is also perishable. Academic origin and specialist talent can help with early product design and credibility, but they do not by themselves create a long-lived moat if larger imaging vendors decide to add similar dose-reduction or interpolation features into broader cath-lab software stacks.

The company is most exposed where it does not control the channel. Corologic describes Angio-FILM as an on-prem clinical imaging workflow product and a software medical device, but the sources do not show named commercial hospital customers, distribution agreements, or integration partnerships with angiography-system manufacturers [corologic.io] [LinkedIn] [Seoul Economic Daily, September 2026]. That leaves an obvious opening for incumbent imaging vendors, because they already sit at the point of image capture and procurement. Corologic also faces a category constraint: its current public positioning is tightly tied to coronary angiography, which is an advantage for focus but limits immediate spillover into broader radiology or non-cardiac imaging unless the company proves that the same technical and regulatory approach generalizes [Asia Economy, September 2026] [VentureSquare, October 2026].

The most plausible 18-month scenario is a race between specialist validation and incumbent absorption. Corologic is the most likely winner if multicenter clinical validation and Korean regulatory progress convert its hospital-origin story into referenceable deployments, because that would give a focused startup credibility that is hard to replicate quickly from outside the cath lab [Asia Economy, September 2026] [Seoul Economic Daily, September 2026]. The status quo is the likely loser if lower-frame-rate imaging can preserve procedural usability while reducing radiation exposure, since that would weaken the clinical case for running conventional acquisition settings by default [VentureSquare, October 2026] [corologic.io]. The reverse is also true. If validation takes longer than expected, incumbent angiography-platform vendors retain the advantage simply by owning purchasing relationships and the underlying workflow, and Corologic remains a feature contender rather than a category-defining platform [Seoul Economic Daily, September 2026] [Asia Economy, September 2026].

Partially corroborated -- This section relies on corroborated public reporting for Corologic's positioning and team, but competitor names and incumbent segmentation are inferred from the product category rather than directly enumerated in the sources.

Opportunity

PUBLIC

If Corologic executes on both evidence and regulation, the prize is not a narrow imaging add-on but a new workflow standard for coronary angiography, one that lets cath labs accept lower radiation tradeoffs without giving up procedural visibility [Asia Economy, September 2026] [VentureSquare, October 2026].

The headline opportunity is straightforward. Corologic is trying to sit inside a high-stakes clinical imaging workflow with software that improves the usable output of lower-frame-rate coronary angiography in real time, a claim that matters because radiation dose is a persistent constraint for both patients and staff in interventional cardiology [Asia Economy, September 2026] [corologic.io]. The path from interesting demo to meaningful company is still early, but there are two public signals that make the upside more than aspirational: first, the product is described as a software medical device for the cardiac catheterization laboratory, which implies a defined clinical use case rather than a general AI toolkit [LinkedIn]; second, a team tied to Seoul National University Bundang Hospital and supported by Kakao Ventures and Seoul National University Technology Holdings has already secured seed backing to pursue multicenter validation and regulatory approvals in Korea and the U.S. [Seoul Economic Daily, September 2026] [Asia Economy, September 2026]. If those steps hold, Corologic could become a default software layer for dose-reduced coronary angiography in hospitals that want better image continuity without adding new imaging hardware.

The upside breaks into a small number of clear scale paths.

Scenario	What happens	Catalyst	Why it's plausible
Win the dose-reduction standard	Angio-FILM becomes a recognized software layer for lower-dose coronary angiography in Korean cath labs, then expands into additional hospital systems	Multicenter clinical validation plus Korean regulatory progress [Asia Economy, September 2026]	The product is already positioned around a specific clinical pain point, and the company says it is pursuing multicenter validation and Korean approval rather than a broad consumer rollout [Asia Economy, September 2026] [Seoul Economic Daily, September 2026]
Become the embedded imaging stack	Corologic moves from stand-alone software into integration with on-prem clinical imaging workflows and angiography equipment environments	Demonstrated workflow fit in the cath lab and partnerships around deployment [corologic.io] [KORIT, September 2026]	The company publicly describes on-prem clinical imaging workflows, while the CTO is reported to have experience in cardiovascular angiography equipment and related workflows, which makes product integration a plausible expansion path [corologic.io] [KORIT, September 2026]
Cross-border regulatory expansion	Corologic uses Korean validation as the base case, then seeks FDA 510(k) clearance and ISO 13485 to sell into a wider medical-device software market	Successful domestic evidence package and quality-system buildout [Asia Economy, September 2026]	The company has already named FDA 510(k) clearance and ISO 13485 certification as part of the use of proceeds after the seed round, suggesting that management is building for a regulated export pathway from the outset [Asia Economy, September 2026]

What compounding looks like here is not consumer network effect. It is workflow entrenchment, clinical evidence, and regulatory credibility reinforcing each other. If Angio-FILM can show that lower-frame-rate imaging still preserves enough procedural visibility in real-world cath lab use, each hospital deployment could improve the next sale: clinicians create referenceability, multicenter data strengthens the approval package, approvals widen the addressable buyer set, and deeper workflow integration raises switching costs [Asia Economy, September 2026] [corologic.io]. The early signs are modest but visible. Corologic already frames the product around real-time operation, on-prem deployment, and a specific interventional setting, which usually matters more in medtech software than broad model novelty because procurement turns on clinical fit, validation burden, and installation friction [corologic.io] [LinkedIn].

The size of the win is harder to quantify from public data because no credible market-sizing source or direct public comparable was supplied in the reviewed materials. Even so, the shape of the upside is still legible. If Corologic were to become a clinically validated and regulatorily cleared software layer used across a meaningful share of coronary angiography workflows in Korea and then selected overseas markets, the outcome could resemble a valuable strategic imaging-software asset rather than a feature business (scenario, not a forecast) [Asia Economy, September 2026] [Seoul Economic Daily, September 2026]. In practical terms, that would mean moving from a single-product academic spinout into a platform position inside interventional cardiology imaging, with the strongest upside tied to evidence that the software changes the standard dose-quality tradeoff rather than merely improving image aesthetics [VentureSquare, October 2026] [KORIT, September 2026].

Partially corroborated -- Based primarily on named publisher coverage and company materials, with no independent public market-sizing data or disclosed commercial metrics in this section.

Sources

Open sources

1. [corologic.io] CoroLogic | Lower-dose coronary angiography, restored by AI | https://www.corologic.io/

2. [Seoul Economic Daily, September 2026] Cardiovascular AI Startup Corologic Raises Seed Funding From Kakao Ventures | https://en.sedaily.com/technology/2026/09/15/cardiovascular-ai-startup-corologic-raises-seed-funding

3. [KORIT, September 2026] CoroLogic、Kakao Ventures・ソウル大技術持株からシード資金調達 | https://www.korit.jp/funding/healthcare/platum-corologic-kakaoventures-seed-260917/

4. [Asia Economy, September 2026] Cardiovascular AI Startup Corologic Secures Seed Funding from Kakao Ventures and Seoul National University Holdings | https://www.asiae.co.kr/en/article/2026091508144099495

5. [LinkedIn] Jayden Won | LG Chem | LinkedIn | https://www.linkedin.com/in/jayden-won/

6. [corologic.io, retrieved 2026] CoroLogic | Lower-dose coronary angiography, restored by AI | https://www.corologic.io/

7. [LinkedIn, retrieved 2026] Jayden Won | LG Chem | LinkedIn | https://www.linkedin.com/in/jayden-won/

8. [VentureSquare, October 2026] 코로로직, X선 촬영 절반으로 줄이고 AI로 영상 복원한다 | https://www.venturesquare.net/1117395/

9. [EDAILY, September 2026] [VC's Pick] The AI That Played a Match Against Lee Sedol 9-dan… Enhance Secures 51.2 Billion Investment | https://en.edaily.co.kr/news/eda202609195052/